ClinicalTrials.gg
CompletedNCT07349602Updated Jan 22, 2026

Evaluation of Outcomes of Surgical Treatment for Nonspecific Infectious Spondylodiscitis Via Posterior Approach in One Center.

An interventional study of Posterior approach to infection site in Spondylodiscitis, Spinal Infection and Spondylitis, sponsored by Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty. Completed at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 10 months after the study started (first participant enrolled Jan 2019, registered Nov 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Non-specific spondylodiscitis is a bacterial infection of the spine that in some cases requires surgical treatment. The basis of surgical treatment is the removal of affected tissues. In this case, the supportive function of the affected area is lost, which also requires stable fixation. Access to the affected part of the spine can be achieved through both anterior and posterior approaches. There is no reliable data yet confirming the advantages of each approach. Our study demonstrated successful surgical treatment of infection foci using posterior approach, no neurological or other complications were occurred. Older patients shown differences in hemoglobin levels, postoperative pain scores, the number of affected vertebrae, types of bacteria and recurrent rate.

Read the detailed description

This retrospective study was conducted on 38 patients with spondylodiscitis treated using a posterior approach. Clinical data were evaluated in four age groups: under 39 years, 40-49 years, and 50-59 years and over 60.

02

Conditions studied

  • Spondylodiscitis
  • Spinal Infection
  • Spondylitis
  • Discitis
  • Osteomyelitis
  • Pyogenic Infections

Keywords

  • pyogenic
  • Spondylodiscitis
  • posterior approach
  • microbiological profiles
03

In context

Discitis

24 studies on the registry are indexed under Discitis; 5 are open to participants now.

Browse Discitis studies →

Lead sponsor

Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- a deep infection affecting intervertebral discs and adjacent vertebral bodies in thoracolumbar spine region which were classified as B.3.1-2 and C2-C4 according to the Pola classification

Exclusion criteria

Exclusion Criteria:

  • cervical spine region infection
  • unwilling to participate in the study,
  • patients with SD of a specific etiology
  • patients who received only conservative treatment,
  • patients with intradural infections.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Posterial approach

    All patients with spondilodiscitis admitted to surgical treatment in one center. During the operation, a posterior approach was used to access the source of infection. The incision of the skin, subcutaneous fat, and aponeurosis was made with the patient in the prone position, projecting through the spinous processes of the vertebrae above the infection site and one adjacent vertebra.

    Procedure: Posterior approach to infection site

Interventions

  • ProcedurePosterior approach to infection site

    For the posterior approach, an incision through the skin, subcutaneous fat, and aponeurosis was made with the patient in the prone position, projecting through the spinous processes of the vertebrae above the infection site and one adjacent vertebra. In all cases, a thorough exploration and debridement of the infection site was performed. Bone biopsies were taken from suspected infection sites in all patients for culture.

06

What researchers measure

Primary outcomes

  1. Surgery time

    Surgery time in minutes

    Time frame: From enrollment to the end of surgery at 1 year

  2. Hospital stays

    Hospital stays in day

    Time frame: From enrollment to the end of surgery at 1 year

  3. Re-operation

    Re-operation number

    Time frame: From enrollment to the 1-year post-surgical treatment follow-up period

  4. Health Questionnaire EuroQol 5 Dimension five levels (EQ-5D-5L)

    The EQ-5D-5L descriptive system uses five dimensions and five levels of severity in each dimension. TThe five dimensions include mobility, self-care, activities of daily living, pain and discomfort, and anxiety and depression. The five levels in each dimension are worded as (1) 'not /no problems', (2) 'slight problems', (3) 'moderate problems', (4) 'severe problems' and (5) 'unable to' (mobility, self-care, usual activities), 'extreme' (pain/depression), or 'extremely' (anxiety/depression). Their responses are coded as a number (1, 2, 3, 4 or 5) that corresponds to the respective level of severity: 1 indicates no problems, 2-4 some problems and 3 extreme problems. In this way, a person's health state profile can be defined by a 5-digit number, ranging from 11111 (having no problems in any of the dimensions) to 55555 (having extreme problems in all the dimensions). The assigning of a value to an EQ-5D state is based on the time trade-off (TTO) approach.

    Time frame: From enrollment to the end of surgery at 1 year

  5. VAS-pain after surgery

    VAS-pain on the 2nd day after surgery. Visual analog scale (0-10 VAS) and it was categorized using the following terms : no pain (0), mild (1-3), moderate (4-6), severe (7-9), or worse pain.

    Time frame: On the 2nd day after surgery

  6. VAS-pain after discharge

    VAS-pain on the 2nd day after discharge. Visual analog scale (0-10 VAS) and it was categorized using the following terms : no pain (0), mild (1-3), moderate (4-6), severe (7-9), or worse pain.

    Time frame: On the 2nd day after discharge

  7. Blood loss during surgery

    Blood loss during surgery in ml

    Time frame: During the intervention

  8. Procalcitonin

    Procalcitonin level in the blood in ng/mL

    Time frame: On the 2nd day after surgery

  9. C-reactive protein

    C-reactive protein in the blood in mg/L (Less than less than 3 mg/L consider be normal)

    Time frame: On the 2nd day after surgery

  10. ESR

    Erythrocyte sedimentation rate in mm/hr. Normal ESR ; \<20mm/hr.

    Time frame: On the 2nd day after surgery

  11. White blood cells

    White blood cells. The normal number of WBCs in the blood is 4.5 to 11.0 × 109/L.

    Time frame: On the 2nd day after surgery

  12. Hemoglobin

    Hemoglobin level in grams per deciliter. Normal hemoglobin for men ranges from 13.5 to 17.5 g/dL. Normal range for women is 12.0 to 15.5 g/dL.

    Time frame: On the 2nd day after surgery

07

Study locations

1 site
  • Federal Center of Traumatology, Orthopedics and Arthroplasty
    Cheboksary, Chuvashskaya Respublika 428020, Russia
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07349602
Lead sponsor
Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Jan 1, 2019
Primary completion
Jan 1, 2023
Completion
Jan 1, 2023
Last update
Jan 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion